MA11.05 Indoleamine 2,3-Dioxygenase Expression in Non-Small-Cell Lung Cancer: Analyses of Prevalence, Clinical Correlations and Prognostic Impact

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.406
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Indoleamine 2,3-Dioxygenase as a Prognostic Factor in Patients With Non-Small Cell Lung Cancer

Journal of Clinical & Cellular Immunology
2014English

Indoleamine 2,3-Dioxygenase Expression in Human Cancers: Clinical and Immunologic Perspectives

Clinical Cancer Research
Cancer ResearchOncology
2011English

Prognostic Significance of FoxM1 Expression in Non-Small Cell Lung Cancer

Journal of Thoracic Disease
PulmonaryRespiratory Medicine
2016English

Indoleamine 2,3-Dioxygenase 1 (IDO1)

Science-Business eXchange
2012English

Indoleamine 2,3-Dioxygenase Expression Pattern in the Tumor Microenvironment Predicts Clinical Outcome in Early Stage Cervical Cancer

Frontiers in Immunology
AllergyImmunology
2018English

Adverse Prognostic Impact of TGFB1 T869C Polymorphism in Non-Small-Cell Lung Cancer

OncoTargets and Therapy
OncologyPharmacology
2017English

Prognostic Implications of Ezrin and Phosphorylated Ezrin Expression in Non-Small Cell Lung Cancer

BMC Cancer
Cancer ResearchOncologyGenetics
2014English

Aryl Hydrocarbon Receptor Signaling Mediates Expression of Indoleamine 2,3-Dioxygenase

Biochemical and Biophysical Research Communications
BiochemistryCell BiologyMolecular BiologyBiophysics
2008English

Prognostic Impact of Serum Transthyretin in Patients With Non‑small Cell Lung Cancer

Molecular and Clinical Oncology
Cancer ResearchOncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy